Temple research paves the way for first Phase 1/2 clinical trials of CRISPR-based therapy for HIV

For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University have been developing and refining CRISPR-based gene-editing technology for the treatment of human immunodeficiency virus type 1 (HIV) infection.

Generated by Feedzy